Vericel Corp
NASDAQ:VCEL

Watchlist Manager
Vericel Corp Logo
Vericel Corp
NASDAQ:VCEL
Watchlist
Price: 59.11 USD 4.23% Market Closed
Market Cap: 2.9B USD
Have any thoughts about
Vericel Corp?
Write Note

Vericel Corp
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Vericel Corp
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Vericel Corp
NASDAQ:VCEL
Gross Profit
$162.1m
CAGR 3-Years
15%
CAGR 5-Years
17%
CAGR 10-Years
39%
Abbvie Inc
NYSE:ABBV
Gross Profit
$37.3B
CAGR 3-Years
0%
CAGR 5-Years
8%
CAGR 10-Years
9%
Gilead Sciences Inc
NASDAQ:GILD
Gross Profit
$22B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Gross Profit
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Gross Profit
$9.2B
CAGR 3-Years
13%
CAGR 5-Years
24%
CAGR 10-Years
29%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Gross Profit
$12B
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
17%
No Stocks Found

Vericel Corp
Glance View

Market Cap
2.9B USD
Industry
Biotechnology

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 281 full-time employees. The firm is focused on therapies for the sports medicine and severe burn care markets. The company markets two autologous cell therapy products in the United States, which include MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). MACI is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel is a permanent skin replacement humanitarian use device (HUD) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area (TBSA). Its NexoBrid, is a registration-stage, topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns.

VCEL Intrinsic Value
29.41 USD
Overvaluation 50%
Intrinsic Value
Price

See Also

What is Vericel Corp's Gross Profit?
Gross Profit
162.1m USD

Based on the financial report for Sep 30, 2024, Vericel Corp's Gross Profit amounts to 162.1m USD.

What is Vericel Corp's Gross Profit growth rate?
Gross Profit CAGR 10Y
39%

Over the last year, the Gross Profit growth was 29%. The average annual Gross Profit growth rates for Vericel Corp have been 15% over the past three years , 17% over the past five years , and 39% over the past ten years .

Back to Top